The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn’s Disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Self-citationTuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
Development of a Crohn's Disease Activity Index
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80163-1 · Cited by 3,152
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · PubMed · Cited by 3,147
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Self-citationInfliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752
Self-citationInfliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226
Self-citationInfluence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Self-citationManagement of Crohn's Disease in Adults
Lichtenstein, G. R., Hanauer, S. B., & Sandborn, W. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.168 · Cited by 1,173
Rutgeerts, P., D'Haens, G., Targan, S., Vasiliauskas, E., Hanauer, S. B., Present, D. H., Mayer, L., Van Hogezand, R. A., Braakman, T., DeWoody, K. L., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70332-x · Cited by 1,080
Self-citationREINECKER, H.-C., STEFFEN, M., WITTHOEFT, T., PFLUEGER, I., SCHREIBER, S., MacDERMOTT, R. P., & RAEDLER, A. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1993.tb05997.x · Cited by 856
Self-citationIrvine, E. J., Feagan, B., Rochon, J., Archambault, A., Fedorak, R. N., Groll, A., Kinnear, D., Saibil, F., & McDonald, J. W. D. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90585-1 · Cited by 712
Self-citationTumour necrosis factor alpha in stool as a marker of intestinal inflammation
Braegger, C. P., Nicholls, S., Murch, S. H., MacDonald, T. T., & Stephens, S. (1992) · The Lancet · doi:10.1016/0140-6736(92)90999-j · Cited by 683
van de Putte, L. B. A., Atkins, C., Malaise, M., Sany, J., Russell, A. S., van Riel, P. L. C. M., Settas, L., Bijlsma, J. W., Todesco, S., Dougados, M., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.013052 · Cited by 617
Farrell, R. J., Alsahli, M., Jeen, Y.-T., Falchuk, K. R., Peppercorn, M. A., & Michetti, P. (2003) · Gastroenterology · doi:10.1053/gast.2003.50145 · Cited by 550
Murch, S. H., Braegger, C. P., Walker-Smith, J. A., & MacDonald, T. T. (1993) · Gut · doi:10.1136/gut.34.12.1705 · Cited by 520
Tumour necrosis factor and Crohn's disease.
Van Deventer, S. J. (1997) · Gut · doi:10.1136/gut.40.4.443 · Cited by 500
Murch, S. H., Lamkin, V. A., Savage, M. O., Walker-Smith, J. A., & MacDonald, T. T. (1991) · Gut · doi:10.1136/gut.32.8.913 · Cited by 482
Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease
Stack, W., Mann, S., Roy, A., Heath, P., Sopwith, M., Freeman, J., Holmes, G., Long, R., Forbes, A., Kamm, M., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)80083-9 · Cited by 384
Self-citationSerum levels of C‐reactive protein in Crohn's disease and ulcerative colitis
FAGAN, E. A., DYCK, R. F., MATON, P. N., HODGSON, H. J. F., CHADWICK, V. S., PETRIE, A., & PEPYS, M. B. (1982) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1982.tb02244.x · Cited by 311
Management of Crohn's disease in adults
Hanauer, S. B., Sandborn, W., & The Practice Parameters Committee of the American College of Gastroenterology (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03671.x · Cited by 261
Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease
Schreiber, S., Nikolaus, S., Hampe, J., Hämling, J., Koop, I., Groessner, B., Lochs, H., & Raedler, A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)03339-x · Cited by 252
Self-citationChoy, E. H. S. (2002) · Rheumatology · doi:10.1093/rheumatology/41.10.1133 · Cited by 213
Su, C., Lichtenstein, G. R., Krok, K., Brensinger, C. M., & Lewis, J. D. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.024 · Cited by 212
A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease
Brignola, C., Campieri, M., Bazzocchi, G., Farruggia, P., Tragnone, A., & Lanfranchi, G. A. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90206-4 · Cited by 159
Mechanisms in failure of infliximab for Crohn's disease
Nikolaus, S., Raedler, A., Kühbacher, T., Sfikas, N., Fölsch, U. R., & Schreiber, S. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02871-3 · Cited by 136
Self-citationStatistical Considerations for Multiplicity in Confirmatory Protocols
Koch, G. G., & Gansky, S. A. (1996) · Drug Information Journal · doi:10.1177/009286159603000228 · Cited by 131
Poullis, A. P., Zar, S., Sundaram, K. K., Moodie, S. J., Risley, P., Theodossi, A., & Mendall, M. A. (2002) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200204000-00013 · Cited by 122
Rutgeerts, P., Lemmens, L., Assche, G. V., Noman, M., Borghini-Fuhrer, I., & Goedkoop, R. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01414.x · Cited by 98
Self-citationPreventing antibodies to infliximab in patients with Crohn's disease: Optimize not immunize
Sandborn, W. J. (2003) · Gastroenterology · doi:10.1053/gast.2003.50182 · Cited by 85
Use of anti-tumour necrosis factor agents in inflammatory bowel disease
Schreiber, S., Campieri, M., Colombel, J., van Deventer, S. J. H., Feagan, B., Fedorak, R. N., Forbes, A., Gassull, M. À., Jp, G., van Hogezand, R. A., et al. (2001) · International Journal of Colorectal Disease · doi:10.1007/s003840100285 · Cited by 49
Self-citationMaintenance infliximab for Crohn's disease
Hanauer, S. B. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11537-6 · Cited by 44
Tromm, A., Tromm, C. D., Hüppe, D., Schwegler, U., Krieg, M., & May, B. (1992) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529209011182 · Cited by 43
Nikolaus, S., Freitag, S., Krawczak, M., & Schreiber, S. (2008) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200801001-00004 · Cited by 10
Self-citation
Cited by
Inflammatory bowel disease: clinical aspects and established and evolving therapies
Baumgart, D. C., & Sandborn, W. J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60751-x · Cited by 1,920
Peyrin-Biroulet, L., Sandborn, W., Sands, B. E., Reinisch, W., Bemelman, W., Bryant, R. V., D'Haens, G., Dotan, I., Dubinsky, M., Feagan, B., et al. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.233 · Cited by 1,844
Self-citationHanauer, S. B., Sandborn, W. J., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D., Panaccione, R., Wolf, D., & Pollack, P. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.030 · Cited by 1,715
Self-citationTumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Dignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
Metadata
- Authors
- Schreiber, S., Rutgeerts, P., Fedorak, R. N., Khaliq–Kareemi, M., Kamm, M. A., Boivin, M., Bernstein, C. N., Staun, M., Thomsen, O. Ø., & Innes, A.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2005-09
- Volume
- 129
- Issue
- 3
- Pages
- 807-818
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W1964785646
- Cited by
- 580
- References
- 34
- FWCI
- 29.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.